Matches in SemOpenAlex for { <https://semopenalex.org/work/W2214609651> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W2214609651 endingPage "1036" @default.
- W2214609651 startingPage "1031" @default.
- W2214609651 abstract "To evaluate dolutegravir and elvitegravir/cobicistat pharmacokinetics in HIV-negative volunteers up to 10 days after drug cessation.Healthy volunteers received 50 mg of dolutegravir once-daily for 10 days, then underwent a 9 day wash-out period, and then received elvitegravir/cobicistat as part of Stribild(®) (245 mg of tenofovir, 200 mg of emtricitabine, 150 mg of elvitegravir and 150 mg of cobicistat) for 10 days. Serial pharmacokinetic (PK) sampling occurred prior to the final dose of each course and at regular intervals for up to 216 h (10 days) after drug cessation. Concentrations were determined by LC-MS/MS, and PK parameters were illustrated as geometric mean and 90% CI.Seventeen volunteers completed the study. For dolutegravir, plasma terminal elimination t1/2 to the last measurable concentration (within 216 h) was longer than its t1/2 within the dosing interval (0-24 h): 14.3 h (12.9-15.7 h) versus 23.1 h (19.7-26.6 h); conversely, the terminal elimination t1/2 for elvitegravir was lower than its t1/2 within the dosing interval (0-24 h): 10.8 h (9.7-13.0 h) versus 5.2 h (4.7-6.1 h). Dolutegravir concentrations were above the protein-adjusted (PA) IC90 (64 ng/mL) in 100% of subjects after 36 and 48 h and in 94% after 60 and 72 h. All subjects had detectable dolutegravir concentrations at 96 h, a mean of 23.5% above the IC90. Elvitegravir concentrations were above the PA IC95 (45 ng/mL) in 100% of subjects at 24 h, 65% at 36 h but 0% after 48 h.Our data show marked differences in the elimination rates of dolutegravir and elvitegravir following treatment interruption, which is likely to impact the extent to which drug doses can be delayed or missed. They suggest that clinical differences may emerge in patients who have suboptimal adherence." @default.
- W2214609651 created "2016-06-24" @default.
- W2214609651 creator A5007876312 @default.
- W2214609651 creator A5011969265 @default.
- W2214609651 creator A5022857046 @default.
- W2214609651 creator A5041365930 @default.
- W2214609651 creator A5042249868 @default.
- W2214609651 creator A5046182619 @default.
- W2214609651 creator A5054671965 @default.
- W2214609651 creator A5066429649 @default.
- W2214609651 creator A5089793108 @default.
- W2214609651 date "2015-12-17" @default.
- W2214609651 modified "2023-10-15" @default.
- W2214609651 title "Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake" @default.
- W2214609651 cites W1977685796 @default.
- W2214609651 cites W1982419299 @default.
- W2214609651 cites W2003715052 @default.
- W2214609651 cites W2014673451 @default.
- W2214609651 cites W2056596520 @default.
- W2214609651 cites W2061400800 @default.
- W2214609651 cites W2085120686 @default.
- W2214609651 cites W2098330191 @default.
- W2214609651 cites W2103722702 @default.
- W2214609651 cites W2142482736 @default.
- W2214609651 doi "https://doi.org/10.1093/jac/dkv425" @default.
- W2214609651 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26679246" @default.
- W2214609651 hasPublicationYear "2015" @default.
- W2214609651 type Work @default.
- W2214609651 sameAs 2214609651 @default.
- W2214609651 citedByCount "28" @default.
- W2214609651 countsByYear W22146096512016 @default.
- W2214609651 countsByYear W22146096512017 @default.
- W2214609651 countsByYear W22146096512018 @default.
- W2214609651 countsByYear W22146096512019 @default.
- W2214609651 countsByYear W22146096512020 @default.
- W2214609651 countsByYear W22146096512021 @default.
- W2214609651 countsByYear W22146096512022 @default.
- W2214609651 countsByYear W22146096512023 @default.
- W2214609651 crossrefType "journal-article" @default.
- W2214609651 hasAuthorship W2214609651A5007876312 @default.
- W2214609651 hasAuthorship W2214609651A5011969265 @default.
- W2214609651 hasAuthorship W2214609651A5022857046 @default.
- W2214609651 hasAuthorship W2214609651A5041365930 @default.
- W2214609651 hasAuthorship W2214609651A5042249868 @default.
- W2214609651 hasAuthorship W2214609651A5046182619 @default.
- W2214609651 hasAuthorship W2214609651A5054671965 @default.
- W2214609651 hasAuthorship W2214609651A5066429649 @default.
- W2214609651 hasAuthorship W2214609651A5089793108 @default.
- W2214609651 hasBestOaLocation W22146096511 @default.
- W2214609651 hasConcept C112705442 @default.
- W2214609651 hasConcept C142462285 @default.
- W2214609651 hasConcept C159047783 @default.
- W2214609651 hasConcept C2777068322 @default.
- W2214609651 hasConcept C2777288759 @default.
- W2214609651 hasConcept C2779502633 @default.
- W2214609651 hasConcept C2780524789 @default.
- W2214609651 hasConcept C2993143319 @default.
- W2214609651 hasConcept C3013748606 @default.
- W2214609651 hasConcept C71924100 @default.
- W2214609651 hasConcept C98274493 @default.
- W2214609651 hasConceptScore W2214609651C112705442 @default.
- W2214609651 hasConceptScore W2214609651C142462285 @default.
- W2214609651 hasConceptScore W2214609651C159047783 @default.
- W2214609651 hasConceptScore W2214609651C2777068322 @default.
- W2214609651 hasConceptScore W2214609651C2777288759 @default.
- W2214609651 hasConceptScore W2214609651C2779502633 @default.
- W2214609651 hasConceptScore W2214609651C2780524789 @default.
- W2214609651 hasConceptScore W2214609651C2993143319 @default.
- W2214609651 hasConceptScore W2214609651C3013748606 @default.
- W2214609651 hasConceptScore W2214609651C71924100 @default.
- W2214609651 hasConceptScore W2214609651C98274493 @default.
- W2214609651 hasIssue "4" @default.
- W2214609651 hasLocation W22146096511 @default.
- W2214609651 hasLocation W22146096512 @default.
- W2214609651 hasOpenAccess W2214609651 @default.
- W2214609651 hasPrimaryLocation W22146096511 @default.
- W2214609651 hasRelatedWork W1557841390 @default.
- W2214609651 hasRelatedWork W2020610488 @default.
- W2214609651 hasRelatedWork W2021395278 @default.
- W2214609651 hasRelatedWork W2214609651 @default.
- W2214609651 hasRelatedWork W2406931452 @default.
- W2214609651 hasRelatedWork W2583744239 @default.
- W2214609651 hasRelatedWork W2912906273 @default.
- W2214609651 hasRelatedWork W2913317838 @default.
- W2214609651 hasRelatedWork W2914093604 @default.
- W2214609651 hasRelatedWork W3027280232 @default.
- W2214609651 hasVolume "71" @default.
- W2214609651 isParatext "false" @default.
- W2214609651 isRetracted "false" @default.
- W2214609651 magId "2214609651" @default.
- W2214609651 workType "article" @default.